CN105307672B - 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂 - Google Patents

用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂 Download PDF

Info

Publication number
CN105307672B
CN105307672B CN201480034914.8A CN201480034914A CN105307672B CN 105307672 B CN105307672 B CN 105307672B CN 201480034914 A CN201480034914 A CN 201480034914A CN 105307672 B CN105307672 B CN 105307672B
Authority
CN
China
Prior art keywords
amino
carboxy
butyryl
ethoxy
glucagon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480034914.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105307672A (zh
Inventor
U.森斯富斯
T.克鲁塞
J.F.劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN105307672A publication Critical patent/CN105307672A/zh
Application granted granted Critical
Publication of CN105307672B publication Critical patent/CN105307672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480034914.8A 2013-04-18 2014-04-22 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂 Active CN105307672B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP13164272 2013-04-18
EP13164272.0 2013-04-18
US201361814969P 2013-04-23 2013-04-23
US61/814969 2013-04-23
EP13196656.6 2013-12-11
EP13196656 2013-12-11
PCT/EP2014/058084 WO2014170496A1 (en) 2013-04-18 2014-04-22 Stable, protracted glp-1/glucagon receptor co-agonists for medical use

Publications (2)

Publication Number Publication Date
CN105307672A CN105307672A (zh) 2016-02-03
CN105307672B true CN105307672B (zh) 2021-01-05

Family

ID=51730843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480034914.8A Active CN105307672B (zh) 2013-04-18 2014-04-22 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂

Country Status (16)

Country Link
US (3) US9474790B2 (enExample)
EP (1) EP2986313B1 (enExample)
JP (1) JP6594856B2 (enExample)
KR (1) KR20160021758A (enExample)
CN (1) CN105307672B (enExample)
AU (1) AU2014255608B2 (enExample)
BR (1) BR112015025464A2 (enExample)
CA (1) CA2909581A1 (enExample)
MX (1) MX362275B (enExample)
MY (1) MY174727A (enExample)
PL (1) PL2986313T3 (enExample)
RS (1) RS59124B1 (enExample)
RU (1) RU2683039C2 (enExample)
SI (1) SI2986313T1 (enExample)
WO (1) WO2014170496A1 (enExample)
ZA (1) ZA201507010B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
DK2986313T3 (da) * 2013-04-18 2019-08-12 Novo Nordisk As Stabile, protraherendede glp-1/glucagonreceptor-co-agonister til medicinsk anvendelse
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
PT3155017T (pt) * 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20171154A1 (es) * 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
EP4523705A3 (en) 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
SI3402811T1 (sl) * 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
EP3479841A4 (en) 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION THEREOF AND THERAPEUTIC USE THEREOF
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
GB201720187D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
EP4506017A3 (en) 2018-01-03 2025-05-14 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
US11633459B2 (en) 2018-05-04 2023-04-25 Novo Nordisk A/S GIP derivatives and uses thereof
US20200268835A1 (en) 2019-02-27 2020-08-27 Novo Nordisk A/S Compounds For Use in NASH
GB201908424D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
CA3168001A1 (en) * 2020-02-21 2021-08-26 Spitfire Pharma Llc Glp-1r and gcgr agonists, formulations, and methods of use
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088116A2 (en) * 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
CN102918056A (zh) * 2010-03-26 2013-02-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
WO2013041678A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
ZA90533B (en) 1989-02-01 1990-10-31 Shionogi & Co A method for the production of glucagon
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5480867A (en) 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CZ120398A3 (cs) 1995-09-08 1998-12-16 Novo Nordisk A/S Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP2000514041A (ja) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE69727837T2 (de) 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP0971917B1 (en) 1997-12-02 2002-02-06 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
US6353018B1 (en) 1998-10-21 2002-03-05 Novo Nordisk A/S Compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2002527502A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの調製及び使用
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CZ20011831A3 (cs) 1998-12-18 2001-10-17 Novo Nordisk A/S Kondenzované 1,2,4-thiadiazinové deriváty, jejich příprava a pouľití
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2000042023A1 (en) 1999-01-18 2000-07-20 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063191A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
PL351492A1 (en) 1999-04-16 2003-04-22 Reddys Lab Ltd Dr Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
EP1171414A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
EP1171438A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
WO2000063190A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
CA2373680C (en) 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
JP4716641B2 (ja) 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
DE60111534T2 (de) 2000-07-20 2006-05-11 F. Hoffmann-La Roche Ag Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
WO2003062290A1 (en) 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1503283A1 (en) 2003-08-01 2005-02-02 Hewlett-Packard Development Company, L.P. Data processing system and method
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
BR122019021416A2 (enExample) 2003-09-19 2019-12-21
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
MX2007015676A (es) 2005-06-15 2008-02-20 Novo Nordisk Healthcare Ag Conjugacion de la hormona de crecimiento mediada por transglutaminasa.
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP1981977B1 (en) 2006-01-31 2015-12-23 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008151258A2 (en) 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
CA2689557C (en) 2007-06-15 2018-08-14 National Research Council Of Canada Engineered versions of polysialyltransferases with enhanced enzymatic properties
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) * 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
KR20100095441A (ko) 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US8450270B2 (en) * 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
WO2010016940A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
US20100099616A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
ES2401965T3 (es) 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN108892709A (zh) 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
DK2710031T3 (en) 2011-05-18 2018-01-02 Mederis Diabetes Llc IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
UA126465C2 (uk) 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
KR20140043793A (ko) * 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015086733A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918056A (zh) * 2010-03-26 2013-02-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
WO2012088116A2 (en) * 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2013041678A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues

Also Published As

Publication number Publication date
WO2014170496A1 (en) 2014-10-23
AU2014255608B2 (en) 2018-01-25
CA2909581A1 (en) 2014-10-23
US20180044394A1 (en) 2018-02-15
RU2015146600A3 (enExample) 2018-03-29
ZA201507010B (en) 2017-08-30
KR20160021758A (ko) 2016-02-26
RU2683039C2 (ru) 2019-03-26
JP2016526012A (ja) 2016-09-01
EP2986313A1 (en) 2016-02-24
US20160355562A1 (en) 2016-12-08
AU2014255608A1 (en) 2015-10-08
SI2986313T1 (sl) 2019-09-30
BR112015025464A2 (pt) 2017-10-10
RS59124B1 (sr) 2019-09-30
EP2986313B1 (en) 2019-06-12
MX362275B (es) 2019-01-10
US9751927B2 (en) 2017-09-05
MX2015014408A (es) 2017-07-28
MY174727A (en) 2020-05-11
RU2015146600A (ru) 2017-05-24
US9474790B2 (en) 2016-10-25
CN105307672A (zh) 2016-02-03
JP6594856B2 (ja) 2019-10-23
US20150374794A1 (en) 2015-12-31
PL2986313T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
CN105307672B (zh) 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
US10570184B2 (en) GLP-1/glucagon receptor co-agonists for medical use
CN104093735B (zh) 新的胰高血糖素类似物
EP3204408B1 (en) Stable glp-1 based glp-1/glucagon receptor co-agonists
US9963496B2 (en) Stable glucagon analogues and use for treatment of hypoglycaemia
CN102933598A (zh) 新型胰高血糖素类似物
JP2019167361A (ja) 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant